Outlook Therapeutics, Inc. (OTLK)
After hours:
| Previous close | 7.73 |
| Open | 7.75 |
| Bid | 7.54 x 100 |
| Ask | 7.61 x 100 |
| Day's range | 7.53 - 7.82 |
| 52-week range | 4.00 - 40.60 |
| Volume | |
| Avg. volume | 665,343 |
| Market cap | 176.603M |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.00 |
| Earnings date | 16 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 39.91 |
GlobeNewswireOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it will report its financial results for second quarter fiscal year 2024 on Thursday, May 16, 2024. Outlook Therapeutics management will host its inaugural quarterly conference call and live audio webcast to discuss th
- GlobeNewswire
Outlook Therapeutics® to Present at the Retina World Congress 2024
ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at the 2024 Retina World Congress being held May 9-12, 2024 in Fort Lauderdale, FL. Details for the presentations are as follows: Session: Retina UnpluggedPanelist: Russell Trenary, President and Chief Execu
- GlobeNewswire
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at the OIS Retina Innovation Showcase being held May 4, 2024 in Seattle, WA. Details for the presentations are as follows: Innovation Showcase: Company PresentationRussell Trenary, President and Chief Exec
